BIOGRAPHICAL SKETCH
NAME POSITION TITLE Professor Paul Workman FRS FMedSci 1. Chief Executive and President, The Institute of Cancer Research (ICR), London UK 2. Director, CRUK-ICR Centre in association with The Royal Marsden NHS Trust, London UK 3. Harrap Professor of Pharmacology and Therapeutics, University of London, UK
EDUCATION/TRAINING DEGREE INSTITUTION AND LOCATION (if YY FIELD OF STUDY applicable) University of Leicester, UK BSc (Hons) 1973 Biological Sciences University of Leeds, UK PhD 1977 Cancer Pharmacology
A. Personal Statement I am an experienced cancer research scientist with extensive leadership and administrative experience in academia and industry. I am passionate about translating our rapidly emerging understanding of fundamental cancer biology with a sense of urgency into new personalized medicines for cancer patients. I am currently Chief Executive and President of The Institute of Cancer Research (ICR), London and Harrap Professor of Pharmacology and Therapeutics at ICR – a college of the University of London. In addition, I am Director of the CRUK-ICR Centre in association with The Royal Marsden NHS Trust (RM). Furthermore, I am the inaugural Director of the ICR-Imperial College Cancer Research Centre of Excellence in Cancer Research which was established in 2016 to bring together – in synergistic convergence science – Imperial’s strengths in engineering, physical, natural, and data sciences and medicine with ICR’s strengths in basic and applied cancer research, as well as forming the basis for an application to become a CRUK Major Centre, addressing all aspects of cancer prevention, early detection and treatment. ICR came top in REF2014 and ICR/RM has been ranked as one of the top four cancer centres in the world for the impact of its publications (Thomson Reuters Evidence). From 1997 to January 2016, I was Head of the Section/Division of Cancer Therapeutics at ICR and Director of the Cancer Research UK Cancer Therapeutics Unit – the largest non-profit cancer drug discovery group globally and recently assessed as the best in world by external peer review. Before that, I was Head of Cancer Bioscience Section at Zeneca Pharmaceuticals (now AstraZeneca) and earlier was at Stanford University, Glasgow University and Cambridge University. I was a scientific founder of the biotechnology companies Piramed Pharma (acquired by Roche for USD 175 million) and Chroma Therapeutics. My personal research focuses on cancer drug discovery, molecular pharmacology and chemical biology – publishing >565 research articles with 19K citations and an H-index of 74 (Web of Science). I have been instrumental in more than 20 drugs entering clinical trials, including protein kinase, PI3 kinase and HSP90 inhibitors. I conceived and exemplified the Pharmacologic Audit Trail for decision-making in preclinical discovery and clinical drug development. I have promoted and exemplified the centre of excellence and team science model for academic drug discovery, while also collaborating extensively with industry. I continue to run an active research laboratory and my current interests are in the discovery and development of innovative personalized medicines; novel drug targets; extending the druggable cancer genome; chemical probes; the HSF1 stress pathway; and overcoming adaptive feedback loops, clonal evolution and drug resistance. As Chief Executive and President of ICR, I have overall responsibility for all aspects of the organization and enjoy the opportunity to guide basic, translational and clinical research. Externally, I am a Non-Executive Director of Storm Therapeutics, the RM and the non-profit Chemical Probes Portal. In addition to numerous previous advisory roles, I am currently a member of a number of advisory boards,
PHS 398/2590 (Rev. 06/09) Page 1 Biographical Sketch Format Page
serve on the editorial board of several journals, and am Deputy Editor of Molecular Cancer Therapeutics and a Reviews Editor of Cancer Cell. I write, blog and lecture on cancer research, cancer drugs and the drug discovery and development ecosystem. I have received numerous honours and awards (see next section).
B. Positions and Honours Positions 1976-79, Postdoctoral Scientist, MRC Clinical Oncology Unit, Cambridge University, UK 1979-83, Limited Tenure Appointment (MRC Grade 2), MRC Clinical Oncology Unit, Cambridge University, UK 1983-87, Tenured Appointment (MRC Grade 1), MRC Clinical Oncology Unit, Cambridge University, UK 1987, Senior Appointment (MRC Grade 2), MRC Clinical Oncology Unit, Cambridge University, UK 1987-1990, MRC Special Appointment (Professorial equivalent), MRC Clinical Oncology Unit, Cambridge University, UK 1990, UICC Visiting Fellow, Stanford University and Stanford Research International, CA, USA 1991-93, Director of Laboratory Research and CRC Professor of Experimental Cancer Therapy, Department of Medical Oncology, CRC Beatson Laboratories, University of Glasgow, UK 1993-97, Head of Bioscience Section, Zeneca Pharmaceuticals (now AstraZeneca) 1997-2016, Director, CRUK Cancer Therapeutics Unit and Head of Division/Section of Cancer Therapeutics, The Institute of Cancer Research, London, UK (ICR) 1997-present, Team Leader, Signal Transduction and Molecular Pharmacology, ICR 1997-present, Harrap Professor of Pharmacology and Therapeutics, ICR 2014, July-November Interim Chief Executive, ICR 2011-2014, Deputy Chief Executive, ICR 2014-present, Chief Executive and President, ICR 2014-present, Director, CRUK-ICR Centre in association with the RM 2016-present, Director, ICR and Imperial College Cancer Research Centre of Excellence
Honours 1985 European School of Oncology Award for Excellence in Oncology Research 1990 UICC ICRETT Fellowship 1991 Cancer Research UK Life Fellow 1993 External Professor of Cancer Pharmacology, Institute of Cancer Studies, University of Leeds UK 1986 Visiting Professor in Pharmacology, School of Biological Sciences, University of Manchester UK 1999 Tannlege Olav Aase og Feu Memorial Lecture, Norwegian Cancer Forum 2001 Fellow of the Royal Society of Biology 2002 Fellow of the Academy of Medical Sciences 2002 Perkin Elmer Life Sciences Lecture, British Association for Cancer Research 2002 Merlin Lecture of Cancer Research UK 2003 Bruce Cain Memorial Award Lecture of the New Zealand Society for Oncology 2006 Dutch New Drug Development Office (NDDO) Award for Cancer Drug Development 2007 ICON Distinguished Lecture of the University of Manchester 2007 Fellow of the Royal Society of Medicine 2009 Honorary DSc University of Leicester UK 2009 Tom Connors Award Lecture of the British Association for Cancer Research and National Cancer Research Institute 2010 Royal Society of Chemistry George and Christine Sosnovsky Award in Cancer Therapy 2010 Fellow of the Royal Society of Chemistry 2011 Bruce Cain Memorial Award Lecture of the New Zealand Society for Oncology 2012 Lineberger Lecture, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA 2012 American Association of Cancer Research Team Science Award (PW Team Leader) 2012 Royal Society of Chemistry World Entrepreneur of the Year Award 2013 Cancer Research UK Translational Cancer Research Prize (with Laurence Pearl) 2014 International Raymond Bourgine Award for Excellence in Cancer Research 2014 Fellow of the European Academy Cancer Sciences 2015 British Pharmacological Society Putting UK Pharmacology on the Map Award (to ICR) PHS 398/2590 (Rev. 06/09) Page 2 Biographical Sketch Format Page
2016 Fellow of the Royal Society 2016 Evening Standard Progress 1000 list of most influential people in London 2016 Cancer Research Innovation Spain (CRIS) Award for Services to Cancer Research 2017 Honorary DSc University of Leeds UK 2017 Honorary Fellow University of Cumbria 2017 Patrick Johnston Memorial Lecture 2017 Queens’s Anniversary Prize (for drug discovery, to ICR)
C. Selected Peer-Reviewed Publications (from a total of >565)
1. Wedge DC, Gundem G, Mitchell T, Woodcock DJ, Martincorena I, Ghori M, Zamora J, Butler A, Whitaker H, Kote-Jarai Z, Alexandrov LB, Van Loo P, Massie CE, Dentro S, Warren AY, Verrill C, Berney DM, Dennis N, Merson S, Hawkins S, Howat W, Yu Y-J, Lambert A, Kay J, Kremeyer B, Karaszi K, Luxton H, Camacho N, Marsden L, Edwards S, Matthews L, Bo V, Leongamornlert D, McLaren S, Ng A, Yu Y, Zhang H, Dadaev T, Thomas S, Easton DF, Ahmed M, Bancroft E, Fisher C, Livni N, Nicol D, Tavaré S, Gill P, Greenman C, Khoo V, Van As N, Kumar P, Ogden C, Cahill D, Thompson A, Mayer E, Rowe E, Dudderidge T, Gnanapragasam V, Shah NC, Raine K, Jones D, Menzies A, Stebbings L, Teague J, Hazell S, CAMCAP study group, de Bono J, Attard A, Isaacs W, Visakorpi T, Fraser M, Boutros PC, Bristow RG, Workman P, Sander C, The TCGA consortium, Hamdy FC, Futreal A, McDermott U, Al-Lazikani B, Lynch AG, Bova GS, Foster CS, Brewer DS, Neal D, Cooper CS, Eeles RA. Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. Nature Genetics in press.
2. Fok JHL, Hedayat S, Zhang L, Aronson LI , Mirabella F, Pawlyn C, Bright MD, Wardell CP, Keats JJ, De Billy E, Rye CS, Chessum NEA, Jones K, Morgan GJ, Eccles SA, Workman P*, Davies F. HSF1: Essential for myeloma cell survival and a promising therapeutic target. Clin Cancer Res in press (*Joint senior author).
3. Whittaker SR, Barlow C, Martin MP, Mancusi C, Wagner S, Self A, Barrie E, Te Poele R, Sharp S, Brown N, Wilson S, Jackson W, Fischer PM, Clarke PA, Walton MI, McDonald E, Blagg J, Noble M, Garrett MD, Workman P*. Molecular profiling and combinatorial activity of CCT068127: A potent CDK2 and CDK9 inhibitor. Mol Oncol 2017 Oct 24. doi: 10.1002/1878-0261.12148 [Epub ahead of print] (*Joint senior author).
4. Antolin A, Tym JE, Komianou A, Collins I, Workman P*, Al-Lazikani B. Objective, quantitative, data-driven assessment of chemical probes. Cell Chem Biol in press (*Joint senior author).
5. Blagg P, Workman P*. Choose and use your chemical probe wisely to explore cancer biology. Cancer Cell 32 268-270 2017 (*Joint senior author).
6. Workman P, Draetta GF, Schellens JH, Bernards R. How much longer will we put up with $100,000 cancer drugs? Cell 168 579-583 2017.
7. Cheeseman MD, Chessum NE, Rye CS, Pasqua AE, Tucker MJ, Wilding B, Evans LE, Lepri S, Richards M, Sharp SY, Ali S, Rowlands M, O'Fee L, Miah A, Hayes A, Henley AT, Powers M, Te Poele R, De Billy E, Pellegrino L, Raynaud F, Burke R, van Montfort RL, Eccles SA, Workman P, Jones K*. Discovery of a chemical probe bisamide (CCT251236): an orally bioavailable efficacious pirin ligand from a Heat Shock Transcription Factor 1 (HSF1) phenotypic screen. J Med Chem 60 180-201 2017 (*Joint senior author).
8. Clarke PA, Ortiz-Ruiz MJ, TePoele R, Adeniji-Popoola O, Box G, Court W, Czasch S, El Bawab S, Esdar C, Ewan K, Gowan S, De Haven Brandon A, Hewitt P, Hobbs SM, Kaufmann W, Mallinger A, Raynaud F, Roe T, Rohdich F, Schiemann K, Simon S, Schneider R, Valenti M, Weigt S, Blagg J, Blaukat A, Dale TC, Eccles SA, Hecht S, Urbahns K, Workman P*, Wienke D. Assessing the mechanism and therapeutic potential of modulators of the human Mediator complex-associated protein kinases. eLife 2016;5:e20722 DOI: 10.7554/eLife.20722 (*Joint senior author).
PHS 398/2590 (Rev. 06/09) Page 3 Biographical Sketch Format Page
9. Rye CS, Chessum NE, Lamont S, Pike KG, Faulder P, Demeritt J, Kemmitt P, Tucker J, Zani L, Cheeseman MD, Isaac R, Goodwin L, Boros J, Raynaud F, Hayes A, Henley AT, de Billy E, Lynch CJ, Sharp SY, Te Poele R, Fee LO, Foote KM, Green S, Workman P*, Jones K. Discovery of 4,6-disubstituted pyrimidines as potent inhibitors of the heat shock factor 1 (HSF1) stress pathway and CDK9. Medchemcomm 7 1580-1586 2016 (*Joint senior author).
10. Ferraldeschi R, Welti J, Powers MV, Yuan W, Smyth T, Seed G, Riisnaes R, Hedayat S, Wang H, Crespo M, Nava Rodrigues D, Figueiredo I, Miranda S, Carreira S, Lyons JF, Sharp S, Plymate SR, Attard G, Wallis N, Workman P*, de Bono JS. Second-generation HSP90 inhibitor onalespib blocks mRNA splicing of androgen receptor variant 7 in prostate cancer cells. Cancer Res 76 2731-2742 2016 (*Joint senior author).
11. Sarker D, Ang JE, Baird R, Kristeleit R, Shah K, Moreno V, Clarke PA, Raynaud FI, Levy G, Ware JA, Mazina K, Lin R, Wu J, Fredrickson J, Spoerke JM, Lackner MR, Yan Y, Friedman LS, Kaye SB, Derynck MK, Workman P, de Bono JS. First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol- 3-kinase (PI3K) inhibitor, in patients with advanced solid tumors. Clin Cancer Res 21 77-86 2015.
12. Workman P. Academia and industry: successes for UK cancer partnership. Nature 510 218 2014.
13. Samant RS, Clarke PA, Workman P*. E3 ubiquitin ligase Cullin-5 modulates multiple molecular and cellular responses to heat shock protein 90 inhibition in human cancer cells. Proc Natl Acad Sci USA 18 6834-6839 2014 (*Senior author).
14. Smith JR, de Billy E, Hobbs S, Powers M, Prodromou C, Pearl L, Clarke PA, Workman P*. Restricting direct interaction of CDC37 with HSP90 does not compromise chaperoning of client proteins. Oncogene 34 15-26 2015 (*Joint senior author).
15. Workman P*, Al-Lazikani B. Drugging cancer genomes. Nat Rev Drug Discov 12 889-890 2013 (*Joint senior author).
16. Bjerke L, Mackay A, Nandhabalan M, Burford A, Jury A, Popov S, Bax DA, Carvalho D, Taylor KR, Vinci M, Bajrami I, McGonnell IM, Lord CJ, Reis RM, Hargrave D, Ashworth A, Workman P, Jones C. Histone H3.3. mutations drive pediatric glioblastoma through upregulation of MYCN. Cancer Discov 3 512-519 2013.
17. Polier S, Samant RS, Clarke PA, Workman P*, Prodromou, Pearl LH. ATP-competitive inhibitors block protein kinase recruitment to the Hsp90-Cdc37 system. Nat Chem Biol 2013; 9 307-312 (*Joint senior author).
18. Patel MN, Halling-Brown MD, Tym JE, Workman P*, Al-Lazikani B. Objective assessment of cancer genes for drug discovery. Nat Rev Drug Discov 12 35-50 2013 (*Joint senior author).
19. Yap TA, Walton MI, Hunter LJ, Valenti M, de Haven Brandon A, Eve PD, Ruddle R, Heaton SP, Henley A, Pickard L, Vijayaraghavan G, Caldwell JJ, Thompson NT, Aherne W, Raynaud FI, Eccles SA, Workman P, Collins I, Garrett MD. Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930. Mol Cancer Ther 10 360-371 2011.
20. Workman P*, Collins I. Probing the probes: fitness factors for small molecule tools. Chem Biol 17 561-577 2010 (*Joint senior author).
21. Raynaud FI, Eccles SA, Patel S, Alix S, Box G, Chuckowree I, Folkes A, Gowan S, de Haven Brandon A, Di Stefano F, Hayes A, Henley AT, Lensun L, Pergl Wilson G, Robson A, Saghir N, Zhyvoloup A, McDonald E, Sheldrake P, Shuttleworth S, Valenti M, Wan NC, Clarke PA, Workman P*. Biological properties of potent inhibitors of Class I phosphatidylinositide 3-kinases: From PI-103 through PI-540, PI-620 to the oral agent GDC- 0941. Mol Cancer Ther 8 1725-1738 2009 (*Joint senior author).
PHS 398/2590 (Rev. 06/09) Page 4 Biographical Sketch Format Page
22. Gaspar N, Sharp SY, Pacey S, Jones C, Walton M, Vassal G, Eccles S, Pearson A, Workman P*. Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells. Cancer Res. 69 966-975 2009 (*Senior author).
23. Smith JR, Clarke PA, de Billy E, Workman P*. Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitors. Oncogene 28 157-169 2009 (*Senior author).
24. Powers MV, Clarke PA, Workman P*. Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. Cancer Cell 14 250-262 2008 (*Senior author).
25. Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl- Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ. The identification of 2-(1H-indazol- 4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J Med Chem 51 5522-5532 2008.
26. Eccles SA, Massey A, Raynaud F, Sharp SY, Box G, Valenti M, Patterson L, de Haven Brandon A, Gowan S, Boxall F, Aherne W, Rowlands M, Hayes A, Martins V, Urban F, Boxall K, Prodromou C, Pearl L, James K, Matthews TP, Cheung KM, Kalusa A, Jones K, McDonald E, Barril X, Brough PA, Cansfield JE, Dymock B, Drysdale MJ, Finch H, Howes R, Hubbard RE, Surgenor A, Webb P, Wood M, Wright L, Workman P*. NVP- AUY922: A novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis and metastasis. Cancer Res 68 2850-2860 2008 (*Joint senior author).
27. Holmes JL, Sharp SY, Hobbs S, Workman P*. Silencing of HSP90 co-chaperone AHA1 expression decreases client protein activation and increases cellular sensitivity to the HSP90 inhibitor 17-allylamino-17- demethoxygeldanamycin (17-AAG). Cancer Res 68 1188-1197 2008 (*Senior author).
28. Brough PA, Aherne W, Barril X, Borgognoni J, Boxall B, Cansfield JE, Cheung KM, Collins I, Davies NGM, Drysdale MJ, Dymock B, Eccles SA, Finch H, Fink A, Hayes A, Howes R, Hubbard RE, James K, Jordan AM, Lockie A, Martins V, Massey A, Matthews T, McDonald E, Northfield CJ, Pearl LH, Prodromou C, Ray S, Raynaud FI, Roughley SD, Sharp SY, Surgenor A, Walmsley DL, Webb P, Wood M, Workman P, Wright L. 4,5- Diaryl isoxazole Hsp90 chaperone inhibitors: Potential therapeutic agents for the treatment of cancer. J Med Chem 51 196-218 2008.
29. Raynaud FI, Eccles S, Clarke PA, Hayes A, Nutley B, Alix S, Henley A, Di Stefano F, Ahmad Z, Guillard S, Bjerke LM, Kelland L, Valenti M, Patterson L, Gowan S, de Haven Brandon A, Hayakawa H, Koizumi T, Ohishi T, Patel S, Saguir N, Parker P, Waterfield M, Workman P *. Pharmacological characterisation of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res 67 5840-5850 2007 (*Joint senior author).
30. Sharp SY, Boxall K, Rowlands M, Prodromou C, Roe SM, Maloney A, Powers M, Clarke PA, Box G, Sanderson S, Patterson L, Matthews TP, Cheung KMJ, Ball K, Hayes A, Raynaud F, Marais R, Pearl L, Eccles S, Aherne W, McDonald E, Workman P*. In vitro biological characterization of a novel, synthetic diaryl pyrazole resorcinol class of HSP90 inhibitors. Cancer Res 67 2206-2216 2007 (*Senior author).
31. Maloney A, Clarke PA, Naaby-Hansen S, Stein R, Koopman JO, Akpan A, Yang A, Zvelebil M, Cramer R, Stimson L, Aherne W, Banerji U, Judson I, Sharp S, Powers M, de Billy E, Salmons J, Walton M, Burlingame A, Waterfield M, Workman P*. Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Cancer Res 67 3239-3253 2007 (*Senior author).
PHS 398/2590 (Rev. 06/09) Page 5 Biographical Sketch Format Page
32. Hayakawa M, Kaizawa H, Kawaguchi K, Ishikawa N, Koizumi T, Ohishi T, Yamano M, Koada M, Ohta M, Tsukamoto S, Raynaud FI, Waterfield MD, Parker P, Workman P. Synthesis and biological evaluation of imidazo[1,2-a]pyridine derivatives as novel PI3 kinase p110alpha inhibitors. Bioorg Med Chem 15 403-12 2007.
33. Cheung KMJ, Matthews TP, James K, Rowlands MG, Boxall KJ, Sharp SY, Maloney A, Roe SM, Prodromou C, Pearl LH, Aherne GW, McDonald E, Workman P. The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors. Bioorg Med Chem Lett 15 3338-3343 2005.
34. Banerji U, O'Donnell A, Scurr M, Pacey S, Stapleton S, Asad Y, Simmons L, Maloney A, Raynaud F, Campbell M, Walton M, Lakhani S, Kaye S, Workman P*, Judson I. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino,17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 23 4152-61 2005. (*Joint senior author).
35. Hostein I, Robertson D, Di Stefano F, Workman P*, Clarke PA. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res 61 4003-9 2001. (*Senior author).
36. Kelland LR, Sharp SY, Rogers PM, Myers TG, Workman P*. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst. 9 1940-1949 1999 (*Senior author).
37. Aboagye EO, Maxwell RJ, Kelson AB, Tracy M, Lewis AD, Graham MA, Horsman MR, Griffiths JR, Workman P. Preclinical evaluation of the fluorinated 2-nitroimidazole N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1- imidazolyl) acetamide (SR-4554) as a probe for the measurement of tumor hypoxia. Cancer Res 57 3314-8 1997.
D. Grants Current (selected Principal Investigator grants – Note: I have received continuous MRC funding from 1976-90 and CRUK funding from 1990-93 and 1997 to date.
• Cancer Research UK – CRUK Cancer Therapeutics Unit quinquennial core funding (Programme); 6 years from 2011; GBP 35,000,000 (PI)
• Wellcome Trust – Mechanism-Based Drug Discovery PhD Training Programme (Programme); 9 years from 2008; GBP 4,900,000 (Programme Director)
• Cancer Research UK – Cancer Research UK Centre Grant to The Institute of Cancer Research/The Royal Marsden (Programme); 3 years from 2014; GBP 12,600,000 (PI and Centre Director)
• Cancer Research UK – Cancer Research UK Centre Grant to the CRUK-ICR Centre in association with The Royal Marsden NHS Trust; 5 years from 2017; GBP 23,000,000 (Centre Director)
• Cancer Research UK – Harrap Chair of Pharmacology and Therapeutics; 20 years from 1997; approx. GBP 100,000 p.a. (Personal Award – contribution to personal salary in recognition of appointment as a CRUK Life Fellow)
• Prostate Cancer UK – Implications to outcome and treatment in prostate cancer (Project); 3 years from 2014; GBP 393,000 (Co-PI)
• Medical Research Council – Confidence in Concept MRC Confidence in Concept (CiC); 1 year from 2017; GBP GBP 320,00 (PI)
PHS 398/2590 (Rev. 06/09) Page 6 Biographical Sketch Format Page
E. Achievements in key domains
• Built and successfully led a series of high-performing teams in academia and industry
• As Chief Executive and President of ICR, achievements include: delivered and published a new Research Strategy joint with the Royal Marsden; ICR ranked top position in the Times Higher Education rankings based on the Research Excellence Framework (REF 2014); ICR ranked in the top five higher education institutions in the world for research according to European Commission U-Multirank and joint first when excluding the measure of the absolute number of research papers published which favours larger organizations; ICR ranked top of among UK Higher Education Institutes for commercial income (2017); increased total ICR income to record GBP 162 million (2015–16); ICR awarded prestigious Regius Professorship in Cancer Research (2016); renewed CRUK-ICR Centre funding at GBP 22.5 million, ECMC funding at GBP 2.5 million, NIHR RM/ICR BRC funding at GBP 43 million; CRUK Cancer Therapeutics Unit funding at GBP 43 million; awarded GBP 30 million from the UK Research Partnership Investment Fund scheme for the new Centre for Drug Discovery building; increased fundraising to record GBP 16 million. In December 2017 ICR was awarded The Queen’s Anniversary Prize for cancer drug discovery leading to global patient benefit
• As Director of ICR’s CRUK Cancer Therapeutics Unit, built and led the Unit to discover 20 drug candidates since 2005, with 9 progressing into clinical trials and abiraterone approved – recognized by the 2012 American Association of Cancer Research Team Science Award (PW Team Leader) and British Pharmacological Society ‘Putting UK Pharmacology on the Map’ Award (2015) as well as the Queen’s Anniversary Prize (2017, see above)
• As a senior leader at (Astra) Zeneca, led the biology of the Project Team that discovered the EGFR tyrosine kinase inhibitor gefitinib (Iressa) – one of the first molecularly targeted drugs that was approved in EGFR mutant non small cell lung cancer; served as a member of a small senior group working with Anderson Consulting (now Accenture) on a project to re-engineer the research function and involved in the subsequent change implementation programme
• As a biotech entrepreneur, was co-founder with Tony Kouzarides in 2000 of Chroma Therapeutics (alliance with GSK in 2009; USD 10 million collaboration with Cell Therapeutics Inc to develop tosedostat in 2011; licensed Esterase Motif Technology and discovery stage therapeutic assets to Macrophage Pharma in 2017); also co-founder with Mike Waterfield and Peter Parker of Piramed Pharma (acquired by Roche for USD 175 million in 2008); and received the Royal Society of Chemistry World Entrepreneur of the Year Award in 2012
• Extensive experience as Chair and Member of numerous boards and committees, including Board Director of Chroma Therapeutics and STORM Therapeutics; Chair of European Association of Cancer Research (EORTC) Pharmacology and Molecular Mechanism Group; Chair of the EORTC New Drug Development Coordinating Committee; Chair and Member of several CRUK Committees, including the main Sicence Funding Grants Committee; Member of EORTC Board and Council; Member of several American Association of Cancer Research (AACR) Committees; Chair of Structural Genomics Consortium Cancer Target Prioritisation Network; Chair of the National Cancer Research Institute (NCRI) Committee on Guidelines for the Welfare and Use of Animals in Cancer Research and its earlier incarnations – publishing a series of highly used and cited guidelines
• As a research scientist, published over 565 research articles and reviews, covering multiple contributions to the discovery of cancer drugs and chemical probes, including PI3 kinase, AKT and HSP90 inhibitors; conceptualized, developed and implemented the Pharmacological Audit Trail for decision-making in drug discovery and development, based on predictive, pharmacokinetic, pharmacodynamics and other biomarkers – an approach now widely adopted in academia and industry; leading to election in 2016 as a Fellow of the Royal Society, the UK’s national science academy, together with numerous other personal honours (see earlier)
PHS 398/2590 (Rev. 06/09) Page 7 Biographical Sketch Format Page
PHS 398/2590 (Rev. 06/09) Page 8 Biographical Sketch Format Page